<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002358</url>
  </required_header>
  <id_info>
    <org_study_id>255A</org_study_id>
    <secondary_id>AI458-903</secondary_id>
    <nct_id>NCT00002358</nct_id>
  </id_info>
  <brief_title>A Study of BV-araU in the Treatment of Varicella-Zoster Viral Disease (VZV) in HIV-Infected Children Who Have Not Had Success With or Who Cannot Take Other Treatments for VZV</brief_title>
  <official_title>Open-Label BV-araU Treatment of Pediatric HIV-Infected Patients With Cutaneous, Visceral, or Ocular Varicella-Zoster Viral Disease Who Have Failed or Are Intolerant of Standard Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <brief_summary>
    <textblock>
      To provide oral sorivudine ( BV-araU ) to pediatric HIV-infected patients with&#xD;
      varicella-zoster viral disease who have failed or are intolerant of alternative therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Any physician qualified to treat pediatric AIDS patients may enroll patients in this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>HIV Infections</condition>
  <condition>Chickenpox</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorivudine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  HIV infection.&#xD;
&#xD;
          -  Cutaneous, visceral, or ocular varicella-zoster viral infection.&#xD;
&#xD;
          -  Refractory or intolerant to acyclovir or foscarnet therapy.&#xD;
&#xD;
          -  Consent of parent or guardian.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Inability to take oral capsules or tolerate liquids.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  5-flucytosine, 5-fluorouracil, high-dose prednisone, or probenecid.&#xD;
&#xD;
        Patients with the following prior condition are excluded:&#xD;
&#xD;
        History of immediate hypersensitivity to nucleoside analogues.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  5-flucytosine, 5-fluorouracil, high-dose prednisone, or probenecid within 4 weeks&#xD;
             prior to study entry.&#xD;
&#xD;
        Required:&#xD;
&#xD;
          -  Prior acyclovir or foscarnet.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Bristol - Myers Squibb Co</name>
      <address>
        <city>Wallingford</city>
        <state>Connecticut</state>
        <zip>06492</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2007</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 1, 2007</last_update_submitted>
  <last_update_submitted_qc>October 1, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2007</last_update_posted>
  <keyword>Herpes Zoster</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <keyword>Antiviral Agents</keyword>
  <keyword>sorivudine</keyword>
  <keyword>Chickenpox</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chickenpox</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorivudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

